Indeed, different performances have been reported depending on the applied PD-L1 IHC clones (personal observations), ALK IHC clones, or EGFR variant analysis method in the same ESP NSCLC EQA schemes, and depending on RAS analysis methods in the ESP mCRC EQA schemes [11, 13, 28]. This evidence concerns the gene ALK and non-small cell lung carcinoma.